Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André(Université Paris-Saclay), Yeon Hee Park(Samsung Medical Center), Sung‐Bae Kim(Ulsan College), Toshimi Takano(The Cancer Institute Hospital), Seock‐Ah Im(Seoul National University Hospital), Giuliano Borges, João Paulo da Silveira Nogueira Lima(AC Camargo Hospital), Sercan Aksoy(Cancer Institute (WIA)), Joaquín Gavilá Gregori(Fundación Instituto Valenciano de Oncología), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giampaolo Bianchini, Rebecca Roylance(University College Hospital), Yasuo Miyoshi, Anne Armstrong(The Christie Hospital), Rajni Sinha(Piedmont Cancer Institute), Manuel Ruíz Borrego(Hospital Universitario Virgen del Rocío), Elgene Lim(St Vincent's Hospital Sydney), Johannes Ettl(TUM Klinikum), Rinat Yerushalmi(Tel Aviv University), Flora Zagouri(Alexandra Hospital), François P. Duhoux(Cliniques Universitaires Saint-Luc), Tanja Fehm(Düsseldorf University Hospital), Dhiraj Gambhire(Daiichi Sankyo (United States)), Jillian Cathcart(Daiichi Sankyo (United States)), Wu Cai(Daiichi Sankyo (United States)), Changan Chu(Daiichi Sankyo (United States)), Anton Egorov(Daiichi Sankyo (United States)), Ian E. Krop(Yale Cancer Center)
Cited by 338Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis